Halozyme Therapeutics Inc (HALO)vsRoyalty Pharma Plc (RPRX)
HALO
Halozyme Therapeutics Inc
$71.53
-0.10%
HEALTHCARE · Cap: $8.24B
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 62% more annual revenue ($2.44B vs $1.51B). RPRX leads profitability with a 33.9% profit margin vs 23.1%. HALO trades at a lower P/E of 24.4x. HALO earns a higher WallStSmart Score of 70/100 (B).
HALO
Strong Buy70
out of 100
Grade: B
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HALO.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 159 in profit
Strong operational efficiency at 49.0%
Revenue surging 42.2% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 31.2% YoY
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Grey zone — moderate risk
Weak financial health signals
Trading at 38.7x book value
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 49.0%. Revenue growth of 42.2% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : HALO
The primary concerns for HALO are Altman Z-Score, Piotroski F-Score, Price/Book. Debt-to-equity of 9.76 is elevated, increasing financial risk.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
HALO profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
HALO carries more volatility with a beta of 0.87 — expect wider price swings.
HALO is growing revenue faster at 42.2% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
HALO scores higher overall (70/100 vs 65/100), backed by strong 23.1% margins and 42.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?